Loading people...
Briggs Morrison is a Managing Partner at MPM Capital, a leading venture capital firm specializing in life sciences. He is a highly experienced investor and executive with a deep background in drug development and clinical research.
Briggs Morrison primarily invests in groundbreaking biotechnology and life science companies. His focus areas include novel therapeutic modalities, drug development, oncology, immunology, and rare diseases, aiming to address significant unmet medical needs.
Briggs Morrison works as a Managing Partner at MPM Capital, a prominent venture capital firm dedicated to investing in and building innovative life science companies.
Briggs Morrison is the Chief Executive Officer of Crossbow Therapeutics and an Executive Partner at MPM BioImpact, based in the Greater Boston Area. In July 2023, he launched Crossbow Therapeutics from stealth with an $80 million Series A funding round to advance novel oncology treatments. Previously, he served as Chief Executive Officer and President of Research and Development at Syndax Pharmaceuticals, guiding the company through its initial public offering. His extensive pharmaceutical leadership experience includes tenures as Chief Medical Officer at AstraZeneca and Head of Clinical Development at both Pfizer and Merck. He completed an internal medicine residency at Massachusetts General Hospital and a medical oncology fellowship at Dana-Farber Cancer Institute after earning his medical degree from the University of Connecticut. Morrison currently focuses on life sciences venture capital and guiding clinical development strategies for emerging biotechnology companies.
Briggs Morrison stands as a highly respected figure in the biotech venture capital landscape, serving as a Managing Partner at MPM Capital. At MPM Capital, a leading firm dedicated to investing in and building innovative life science companies, Morrison leverages his profound expertise to identify and nurture the next generation of therapeutic breakthroughs. His role involves not only capital allocation but also strategic guidance, helping portfolio companies navigate the complex journey from discovery to clinical success.
Morrison's investment focus at MPM Capital is deeply rooted in cutting-edge biotechnology and drug development. He is particularly interested in companies developing novel therapeutic modalities, addressing unmet medical needs in areas such as oncology, immunology, and rare diseases. His keen eye for scientific innovation and clinical potential allows him to back ventures poised to make a significant impact on patient care. He actively participates on the boards of several pioneering biotech companies, including Syndax Pharmaceuticals, Orna Therapeutics, ReNAgade Therapeutics, NextRNA Therapeutics, and ElevateBio, among others, demonstrating his hands-on approach to company building.
Before joining MPM Capital, Briggs Morrison built an impressive career spanning decades in both large pharmaceutical companies and biotech startups. He previously served as the Chief Executive Officer of Syndax Pharmaceuticals, where he led the company through critical development phases. His extensive executive experience also includes significant leadership roles at major pharmaceutical giants. He was the Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, overseeing a vast pipeline of drug candidates. Prior to that, he held the position of Senior Vice President, Clinical Development and Translational Sciences at Pfizer, and was the Head of Oncology Development at Merck.
Morrison's deep understanding of drug development is underpinned by a robust medical and scientific background. He earned his medical degree from the University of Pennsylvania and completed his internal medicine residency at Massachusetts General Hospital. Further specializing, he completed an oncology fellowship at the Dana-Farber Cancer Institute. This blend of clinical expertise, pharmaceutical leadership, and venture capital acumen makes Briggs Morrison a formidable force in advancing life science innovation and bringing life-changing medicines to patients worldwide.
